文献速递糖尿病肥胖与代谢综合征

α-葡萄糖苷酶抑制剂的降糖作用需要胆汁酸信号:小鼠研究

The glucose-lowering effects of α-glucosidase inhibitor require a bile acid signal in mice.
PubMed 文献 · Diabetologia · 2020-02-08

该研究在小鼠中探究胆汁酸信号是否为α-葡萄糖苷酶抑制剂(AGI)降糖作用所必需。AGI通过改变肠道菌群降低不同部位胆汁酸池的微生物胆汁酸水平并增加肠道胆汁酸重吸收;在Fxr敲除小鼠中,AGI的降糖降脂作用部分被削弱。作者认为AGI诱导的胆汁酸信号改变可能部分为其降糖作用所需。

要点

  • AGI改变db/db与HFHS喂养小鼠的肠道菌群,降低各部位胆汁酸池的微生物胆汁酸水平并增加肠道胆汁酸重吸收。
  • AGI诱导的胆汁酸信号变化表现为肝脏FXR激活增加与回肠FXR抑制,与不同器官胆汁酸池大小和组成变化一致。
  • Fxr敲除小鼠中AGI的降糖降脂作用部分被削弱,可能与Fxr依赖的减缓β细胞复制、缓解胰岛素高分泌及改善肝脏糖脂代谢有关。

核心结论

  • AGI通过调节微生物胆汁酸代谢,在不同宿主部位引起胆汁酸池组成变化,从而协调全身胆汁酸信号。
  • AGI诱导的胆汁酸信号改变可能部分为其降糖作用所需。
  • 该研究提示调控微生物胆汁酸与宿主FXR信号对2型糖尿病治疗具有潜在价值。

研究设计与样本

  • 研究使用瘦素受体(Lepr)敲除db/db小鼠和高脂高蔗糖(HFHS)喂养的Fxr(又称Nr1h4)敲除小鼠,给予AGI处理。
  • 评估肝脏、肠道和内分泌胰腺等不同部位的代谢表型与胆汁酸信号。
  • 胆汁酸池谱采用质谱分析,胰岛转录谱采用RNA测序,肠道微生物组采用16S核糖体RNA基因测序。

主要发现

  • AGI在db/db和HFHS喂养小鼠中均降低不同部位胆汁酸池的微生物胆汁酸水平,并通过改变肠道菌群增加肠道胆汁酸重吸收。
  • AGI诱导的胆汁酸信号变化包括肝脏法尼醇X受体(FXR)激活增加和回肠FXR抑制,与不同器官胆汁酸池大小和组成变化一致。
  • 在Fxr敲除小鼠中,AGI的降糖和降脂作用部分被削弱,可能由于AGI对减缓β细胞复制、缓解胰岛素高分泌及改善肝脏脂质和葡萄糖代谢的Fxr依赖效应。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

AIMS/HYPOTHESIS: Bile-acid (BA) signalling is crucial in metabolism homeostasis and has recently been found to mediate the therapeutic effects of glucose-lowering treatments, including α-glucosidase inhibitor (AGI). However, the underlying mechanisms are yet to be clarified. We hypothesised that BA signalling may be required for the glucose-lowering effects and metabolic benefits of AGI. METHODS: Leptin receptor (Lepr)-knockout (KO) db/db mice and high-fat high-sucrose (HFHS)-fed Fxr (also known as Nr1h4)-KO mice were treated with AGI. Metabolic phenotypes and BA signalling in different compartments, including the liver, gut and endocrine pancreas, were evaluated. BA pool profiles were analysed by mass spectrometry. The islet transcription profile was assayed by RNA sequencing. The gut microbiome were assayed by 16S ribosomal RNA gene sequencing. RESULTS: AGI lowered microbial BA levels in BA pools of different compartments in the body, and increased gut BA reabsorption in both db/db and HFHS-fed mouse models via altering the gut microbiome. The AGI-induced changes in BA signalling (including increased activation of farnesoid X receptor [FXR] in the liver and inhibition of FXR in the ileum) echoed the alterations in BA pool size and composition in different organs. In Fxr-KO mice, the glucose- and lipid-lowering effects of AGI were partially abrogated, possibly due to the Fxr-dependent effects of AGI on decelerating beta cell replication, alleviating insulin hypersecretion and improving hepatic lipid and glucose metabolism. CONCLUSIONS/INTERPRETATION: By regulating microbial BA metabolism, AGI elicited diverse changes in BA pool composition in different host compartments to orchestrate BA signalling in the whole body. The AGI-induced changes in BA signalling may be partly required for its glucose-lowering effects. Our study, hence, sheds light on the promising potential of regulating microbial BA and host FXR signalling for the treatment of type 2 diabetes. DATA AVAILABILITY: Sequencing data are available from the BioProject Database (accession no. PRJNA600345; www.ncbi.nlm.nih.gov/bioproject/600345).

来源:Diabetologia,查看原文。版权归原作者所有。

引用

  1. Qiu Y, Shen L, Fu L, et al. The glucose-lowering effects of α-glucosidase inhibitor require a bile acid signal in mice. Diabetologia. 2020. PMID: 32034442. doi:10.1007/s00125-020-05095-7

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。